Background The molecular profiling of patients with advanced non-small-cell lung cancer (NSCLC)
for known oncogenic drivers is recommended during routine care. Nationally, …

PURPOSE HER2 exon 20 insertions and point mutations are oncogenic drivers found in 1%-2%
of patients with non–small-cell lung cancer (NSCLC). No targeted therapy is approved …

IFCT study administering 7.5 mg/kg Bevacizumab plus chemotherapy after chemotherapy
induction did not improve outcomes in extensive SCLC patients. Background This randomized …

Overall survival (OS) with the anaplastic lymphoma kinase (ALK) inhibitor (ALKi) crizotinib
in a large population of unselected patients with ALK-positive non-small-cell lung cancer (…

Background EGFR mutations cause inconsistent response to EGFR tyrosine-kinase inhibitors
(TKI). To better understand these features, we reviewed all cases of EGFR-mutated non-…

Introduction This randomized phase II trial aimed at evaluating the engineered programmed
cell death ligand 1 (PD-L1) antibody atezolizumab in SCLC progressing after first-line …

Objectives To determine whether H elicobacter pylori infection was associated with dementia
and risk of developing dementia in a longitudinal population‐based cohort of elderly adults …

Background Even after resection of early-stage non-small-cell lung cancer (NSCLC), patients
have a high risk of developing recurrence and second primary lung cancer. We aimed to …

Introduction Little is known about the prevalence, prognosis, and response to treatment of
advanced NSCLC harboring multiple genomic alterations. Methods The French Biomarkers …

Background The IONESCO (IFCT-1601) trial assessed the feasibility of neoadjuvant
durvalumab, for early-stage resectable non-small-cell lung cancer (NSCLC). Methods In a …